Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Reeves

Podiatrist, Foot & Ankle Surgery Lake Mary, FL Doctor of Podiatric Medicine

NPI 1740254655 CMS profile 351061

1141 Patterson Ter, Lake Mary, FL 32746

Open in the dashboard

General payments

$424,117

556 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$12,706

1 holding reported · through program year 2025

Through program year 2025, Christopher Reeves of Lake Mary, FL is reported in the CMS Open Payments database as having received $424,117 across 556 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $12,706 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,138 32
2024 General $33,523 54
2023 General $71,034 80
2022 General $152,713 120
2021 General $63,771 97
2020 General $37,805 64
2019 General $48,131 109
2025 Ownership $12,706 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Reeves
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Christopher Reeves were reported at $17,138. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Christopher Reeves Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $48,131 $389 $118–$1,406 $163
2020 $37,805 $191 $62–$691 $114
2021 $63,771 $329 $104–$1,341 $132
2022 $152,713 $419 $125–$1,611 $149
2023 $71,034 $377 $128–$1,164 $160
2024 $33,523 $394 $134–$1,168 $164
2025 $17,138 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $201,216 180 payments
  2. Linvatec Corporation $64,746 14 payments
  3. Stryker Corporation $62,704 68 payments
  4. Smith+Nephew, Inc. $23,433 89 payments
  5. Trilliant Surgical LLC. $19,377 22 payments
  6. Encore Medical, LP $11,279 7 payments
  7. Djo, LLC $9,345 11 payments
  8. Wright Medical Technology, Inc. $7,757 10 payments
  9. Paragon 28, Inc. $6,448 29 payments
  10. Ortho Solutions Inc $5,716 9 payments
  11. Other $12,096 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $265,429 101 payments
  2. Acquisitions $52,165 5 payments
  3. Royalty or License $45,337 56 payments
  4. Travel and Lodging $33,629 100 payments
  5. Food and Beverage $14,383 288 payments
  6. Grant $8,000 1 payment
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,675 3 payments
  8. Education $2,500 2 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM Foot And Ankle $110,074 102 payments
  2. Lapiplasty System Y $74,762 60 payments
  3. AVENGER RADIAL HEAD, +4 STEMS $52,165 5 payments
  4. INFINITY $22,371 12 payments
  5. LAPIPLASTY SYSTEM 1 $15,993 14 payments
  6. INBONE $15,518 5 payments
  7. PROPHECY $14,888 5 payments
  8. INVISION $13,393 4 payments
  9. CARTIMAX $12,099 5 payments
  10. HOFFMANN $11,220 8 payments
  11. Other $136,028 400 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

397

Median for Podiatry: 160

Drug cost

$2,647

Median for Podiatry: $2,368

Branded share of claims

8.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 89 $845
Ondansetron Odt Ondansetron Brand 33 $392
Meloxicam Generic 133 $376
Oxycodone Hcl Generic 81 $307
Celecoxib Generic 19 $257
Ketorolac Tromethamine Generic 13 $246
Doxycycline Hyclate Generic 11 $140
Methylprednisolone Generic 18 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$109,351

Of which drugs: $129

Medicare patients

325

Average age 72

Services billed

2,112

213 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 71%
Ischemic heart disease 36%
Diabetes 27%
Chronic kidney disease 26%
Depression 25%
Osteoporosis 22%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 44 112 $83
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 68 535 $46

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $12
$12 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

556 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record